药物性胆汁淤积的发病机制及诊疗现状

刘梦; 杨玄子; 于乐成

doi:10.3969/j.issn.1001-5256.2019.02.003

药物性胆汁淤积的发病机制及诊疗现状

DOI: 10.3969/j.issn.1001-5256.2019.02.003

解放军东部战区总医院南京中医药大学附属八一医院

详细信息

中图分类号: R575
计量
- 文章访问数: 2194
- HTML全文浏览量: 56
- PDF下载量: 541
- 被引次数: 0
出版历程
- 收稿日期: 2018-12-12
- 出版日期: 2019-02-20

Current status of the pathogenesis, diagnosis, and treatment of drug-induced cholestasis

General Hospital of Eastern Theater Command & Bayi Hospital Affiliated to Nanjing University of Chinese Medicine

摘要

摘要:
药物性胆汁淤积(DRIC)主要包括胆汁淤积型药物性肝损伤和混合型药物性肝损伤,其诊断应参考RUCAM量表判断药物与胆汁淤积之间的因果关系,尤其是充分排除其他病因。肝活组织病理学检查有助于鉴别诊断。发生DRIC后通常应及时停药和避免再刺激,并给予熊去氧胆酸等药物治疗。DRIC发病机制复杂,涉及药物及其代谢产物对肝细胞和胆管树的直接毒性、免疫和炎症反应、药物代谢与外排通路中酶和转运载体的受抑及基因多态性、HLA基因多态性等。深入阐明这些机制,必将有助于DRIC的预警、预防及优化治疗。
- 药物性肝损伤 /
- 胆汁淤积 /
- 诊断 /
- 治疗学
Abstract:
Drug-induced cholestasis ( DRIC) mainly includes cholestasis-type and mixed-type drug-induced liver injury ( DILI) . The Roussel Uclaf Causality Assessment Method scale should be used to determine the causality between drug and cholestasis and other etiologies should be excluded. Liver biopsy may help with differential diagnosis. Drugs should be stopped after the development of DRIC to avoid stimulation, and ursodeoxycholic acid should be administered for treatment. DRIC has a complex pathogenesis, which involves the direct toxicity of drugs and their metabolites on hepatocytes and the biliary tree, immune and inflammatory response, gene polymorphism and inhibition of key enzymes and transporters in the pathways of drug metabolism and efflux, and HLA gene polymorphisms. Clarification of these pathogeneses helps with the early warning, prevention, and optimized treatment of DRIC.
- drug-induced liver injury /
- cholestasis /
- diagnosis /
- therapeutics

HTML全文

参考文献(39)

[1]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[2]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:The diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.

[3]KLEINER DE.Drug-induced liver injury:The hepatic pathologis's approach[J].Gastroenterol Clin North Am, 2017, 46 (2) :273-296.

[4]KLEINER DE, CHALASANI NP, LEE WM, et al.Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J].Hepatology, 2014, 59 (2) :661-670.

[5]PADDA MS, SANCHEZ M, AKHTAR AJ, et al.Drug-induced cholestasis[J].Hepatology, 2011, 53 (4) :1377-1387.

[6]MENGS U, POHL RT, MITCHELLl T.Legalon SIL:The antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning[J].Curr Pharm Biotechnol, 2012, 13 (10) :1964-1970.

[7]deLEMOS AS, GHABRIL M, ROCKEY DC, et al.Amoxicillinclavulanate-induced liver injury[J].Dig Dis Sci, 2016, 61 (8) :2406-2416.

[8]FORNER D, KULAI T, ARNASON T, et al.Ramipril-associated cholestasis in the setting of recurrent drug-induced liver injury[J].Gastroenterol Hepatol Bed Bench, 2017, 10 (2) :143-146.

[9]XU D, WU M, NISHIMURA S, et al.Chimeric TK-NOG mice:A predictive model for cholestatic human liver toxicity[J].JPharmacol Exp Ther, 2015, 352 (2) :274-280.

[10]LEE SY, SCHNEIER A, SCHIANO T, et al.Delayed diagnosis of cholestatic drug-induced liver injury treated with corticosteroid for adrenal insufficiency secondary to miliary tuberculosis[J].Eur Rev Med Pharmacol Sci, 2015, 19 (16) :3046-3049.

[11]NOTENBOOM S, WEIGAND KM, PROOST JH, et al.Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs[J].Eur J Pharm Sci, 2018, 115:175-184.

[12]YE H, NELSON LJ, GMEZ DEL MORAL M, et al.Dissecting the molecular pathophysiology of drug-induced liver injury[J].World J Gastroenterol, 2018, 24 (13) :1373-1385.

[13]NAYUDU SK, BADIPATLA S, NIAZI M, et al.Cholestatic hepatitis with small duct injury associated with celecoxib[J].Case Rep Med, 2013, 2013:315479.

[14]Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.Expert consensus on diagnosis and treatment of quinazoline alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing) [J].J Clin Hepatol, 2017, 33 (9) :1627-1637. (in Chinese) 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见 (2017年, 南京) [J].临床肝胆病杂志, 2017, 33 (9) :1627-1637.

[15]Branch of Hepatobiliary Diseases, China Association of Chinese Medicine;Branch of Chinese Patent Medicine, China Association of Chinese Medicine.Guidelines for the clinical management of herb-induced liver injury[J].J Clin Hepatol, 2016, 32 (5) :835-843. (in Chinese) 中华中医药学会肝胆病分会, 中华中医药学会中成药分会.中草药相关肝损伤临床诊疗指南[J].临床肝胆病杂志, 2016, 32 (5) :835-843.

[16]SLIJEPCEVIC D, ROSCAM ABBING RLP, KATAFUCHI T, et al.Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice[J].Hepatology, 2017, 66 (5) :1631-1643.

[17]PAN Q, ZHANG X, ZHANG L, et al.Solute carrier organic anion transporter family member 3A1 is a bile acid efflux transporter in cholestasis[J].Gastroenterolog, 2018, 155 (5) :1578-1592.

[18]JURˇICA J, DOVRTLOVG, NOSKOVK, et al.Bile acids, nuclear receptors and cytochrome P450[J].Physiol Res, 2016, 65 (Supplementum 4) :s427-s440.

[19]PERREAULT M, WUNSCH E, BIAEK A, et al.Urinary elimination of bile acid glucuronides under severe cholestatic situations:Contribution of hepatic and renal glucuronidation reactions[J].Can J Gastroenterol Hepatol, 2018, 2018:8096314.

[20]GHONEM NS, ASSIS DN, BOYER JL.Fibrates and cholestasis[J].Hepatology, 2015, 62 (2) :635-643.

[21]SUNDARAM V, BJRNSSON ES.Drug-induced cholestasis[J].Hepatol Commun, 2017, 1 (8) :726-735.

[22]GEIER A, WAGNER M, DIETRICH CG, et al.Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration[J].Biochim Biophys Acta, 2007, 1773 (3) :283-308.

[23]KCK K, FERSLEW BC, NETTERBERG I, et al.Risk factors for development of cholestatic drug-induced liver injury:Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4[J].Drug Metab Dispos, 2014, 42 (4) :665-674.

[24]DALY AK, DAY CP.Genetic factors in the pathogenesis of drug-induced liver injury.In:KAPLOWITZ N, DELEVE LD, editors.Drug-induced Liver Disease[M].3rd ed.San Diego:Academic Press, 2012:215-225.

[25]CHOI JH, AHN BM, YI J, et al.MRP2 haplotypes confer differential susceptibility to toxic liver injury[J].Pharmacogenet Genomics, 2007, 17 (6) :403-415.

[26]YUAN J, GUO S, HALL D, et al.Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent[J].AIDS, 2011, 25 (10) :1271-1280.

[27]STEPHENS C, LPEZ-NEVOT M, RUIZ-CABELLO F, et al.HLA al eles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity[J].PLo S One, 2013, 8 (7) :e68111.

[28] HU XQ.Discussion on pathological scoring system of druginduced liver injury[J].Chin J Hepatol, 2012, 20 (3) :176-177. (in Chinese) 胡锡琪.药物性肝损伤组织病理学评分探讨[J].中华肝脏病杂志, 2012, 20 (3) :176-177.

[29]YANG RY, ZHAO XY.Significance of liver histopathological examination in diagnosis and treatment of drug-induced liver injury[J].J Clin Hepatol, 2018, 34 (6) :1172-1175. (in Chinese) 杨瑞园, 赵新颜.肝组织病理学检查在药物性肝损伤诊治中的意义[J].临床肝胆病杂志, 2018, 34 (6) :1172-1175.

[30]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and treatment of cholestasis liver diseases (2015) [J].J Clin Hepatol, 2015, 31 (12) :1989-1999. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.胆汁淤积性肝病诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2015, 31 (12) :1989-1999.

[31]European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver.Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EA-SL) clinical guideline[J].J Hepatol, 2017, 66 (6) :1265-1281.

[32]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACGclinical guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.

[33]DANAN G, TESCHKE R.RUCAM in drug and herb induced liver injury:The update[J].Int J Mol Sci, 2016, 17 (1) :14.

[34]DANAN G, TESCHKE R.Drug-induced liver injury:Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?[J].Drug Saf, 2018, 41 (8) :735-743.

[35]YU YC, FAN Y.Advances in Roussel Uclaf Causality Assessment Method for diagnosis of drug-induced liver injury and its comparison with structured expert opinion process[J].J Clin Hepatol, 2016, 32 (9) :1706-1713. (in Chinese) 于乐成, 范晔.RUCAM诊断药物性肝损伤的进展及其与结构化专家观点评估法的比较[J].临床肝胆病杂志, 2016, 32 (9) :1706-1713.

[36]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.

[37]YU YC, FAN Y, CHEN CW.Rechallenge test for drug-induced liver injury:Possibility for deliberate rechallenge and methods for operation and judgment[J].Chin Hepatol, 2017, 22 (12) :1073-1076. (in Chinese) 于乐成, 范晔, 陈成伟.药物性肝损伤再刺激试验:能否故意?如何操作?如何判断?[J].肝脏, 2017, 22 (12) :1073-1076.

[38]YU YC, FAN Y, CHEN CW.Diagnosis and treatment of druginduced liver injury[J].J Clin Hepatol, 2018, 34 (6) :1160-1165. (in Chinese) 于乐成, 范晔, 陈成伟.药物性肝损伤的诊断和治疗[J].临床肝胆病杂志, 2018, 34 (6) :1160-1165.

[39]FORD R, SCHWARTZ L, DANCEY J, et al.US Food and Drug Administration.Center for Drug Evaluation and Research (CDER) , Center for Biologics Evaluation and Research (CB-ER) .Guidance for industry:Drug-induced liver injury-premarketing clinical evaluation[J].Eur J Cancer, 2009, 45 (2) :268-274.

施引文献

资源附件(0)

访问统计